[
    [
        {
            "time": "",
            "original_text": "贝达药业2019年净利润增33.90% 多款在研新药进展顺利",
            "features": {
                "keywords": [
                    "贝达药业",
                    "净利润",
                    "增长",
                    "在研新药",
                    "进展顺利"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业2019年净利润增33.90% 多款在研新药进展顺利",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "大单品持续放量！贝达药业2019年全年净利2.23亿",
            "features": {
                "keywords": [
                    "贝达药业",
                    "大单品",
                    "放量",
                    "净利",
                    "2019年"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "大单品持续放量！贝达药业2019年全年净利2.23亿",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 4,
                "Headline_Structure": 9,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "肺癌创新药研发有进展，贝达药业2019盈利2亿",
            "features": {
                "keywords": [
                    "肺癌",
                    "创新药",
                    "研发进展",
                    "贝达药业",
                    "盈利"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "肺癌创新药研发有进展，贝达药业2019盈利2亿",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        }
    ]
]